πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

3,067 results for β€œHospital” Clear

  1. Bupivacaine

    Hospital Authority, Hong Kong

    Pain

    approved small molecule completed

    1 trial
  2. Bupivacaine Hydrochloride

    The First People's Hospital of Lianyungang

    Pulmonary Nodule

    approved small molecule active

    1 trial
  3. Busulfan

    The First People's Hospital of Lianyungang

    Thalassemia Major

    approved small molecule completed

    1 trial
  4. Butylphthalide

    The First People's Hospital of Lianyungang

    Focal Epilepsy

    approved small molecule active

    1 trial
  5. Byfavo

    Hospital Authority, Hong Kong

    Bronchoscopy

    approved small molecule completed

    1 trial
  6. CFNB group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial
  7. COVAX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    approved mab active

    1 trial
  8. CSII

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial
  9. CTB group

    The First People's Hospital of Lianyungang

    Post-operative Pain

    approved other active

    1 trial
  10. Calcitriol

    The First People's Hospital of Lianyungang

    Glomerulonephritis

    approved small molecule active

    1 trial
  11. Camrelizumab + chemotherapy+Thalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    approved small molecule active

    1 trial
  12. Chemoembolization and Response-Dependent Resection

    The First People's Hospital of Lianyungang

    Resectable Hepatocellular Carcinoma Beyond Milan Criteria

    approved other active

    1 trial
  13. Chinese Herb Huang-Chi-Wu-Wu-Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracranial Arterial Stenosis

    approved small molecule active

    1 trial
  14. Chlorhexidine gluconate

    Hospital Authority, Hong Kong

    Liver Tumors

    approved small molecule completed

    1 trial
  15. Chloroprocaine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Anesthesia

    approved small molecule completed

    1 trial
  16. Cholecalciferol

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis-associated Peritonitis

    approved small molecule active

    1 trial
  17. Cilostazol

    The First People's Hospital of Lianyungang

    Cerebral Small Vessel Disease

    approved small molecule active

    1 trial
  18. Cinacalcet HCl

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hyperparathyroidism; Secondary, Renal

    approved small molecule completed

    1 trial
  19. Cinobufacini injection

    The First People's Hospital of Lianyungang

    Liver Cancer

    approved small molecule active

    1 trial
  20. Ciprofol

    The First People's Hospital of Lianyungang

    Postoperative Delirium (POD)

    approved small molecule active

    1 trial
  21. Ciprofol

    The First People's Hospital of Lianyungang

    ECMO Treatment

    approved small molecule active

    1 trial
  22. Citrate anticoagulation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sepsis

    approved small molecule active

    1 trial
  23. Clopidogrel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    approved small molecule completed

    1 trial
  24. Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses

    The First People's Hospital of Lianyungang

    HER2 Positive Breast Cancer

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources